Corcept Therapeutics CORT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $164.9M-18.4% | $202.13M-2.7% | $207.64M+6.8% | $194.43M+23.7% | $157.21M-13.6% | ||
| $2.88M+13.3% | $2.55M-44.6% | $4.6M+33.9% | $3.43M+42.9% | $2.4M-18.7% | ||
| $66.27M+2.2% | $64.86M-5.8% | $68.85M+13.8% | $60.47M-0.4% | $60.74M-13.6% | ||
| $145.36M+11.6% | $130.24M+5.0% | $123.98M+19.4% | $103.85M+14.5% | $90.66M+8.7% | ||
| $598K+107% | $289K0.0% | $289K+165% | $109K-61.8% | $285K+1.4% | ||
| $214.5M+8.5% | $197.64M+0.1% | $197.42M+17.7% | $167.76M+9.1% | $153.8M-1.8% | ||
| -$49.6M-1,205% | $4.49M-56.1% | $10.22M-61.7% | $26.68M+681% | $3.42M-86.5% | ||
| -30.1%-32.3pp | 2.2%-2.7pp | 4.9%-8.8pp | 13.7%+11.5pp | 2.2%-11.7pp | ||
| $4.89M-9.9% | $5.42M+7.9% | $5.02M+0.1% | $5.02M-19.1% | $6.2M-7.4% | ||
| -$44.72M-551% | $9.91M-35.0% | $15.24M-51.9% | $31.69M+230% | $9.62M-69.9% | ||
| -$12.95M+9.9% | -$14.38M-225% | -$4.43M-28.0% | -$3.46M+68.4% | -$10.93M-1,000% | ||
| -$31.76M-231% | $24.29M+23.5% | $19.67M-44.0% | $35.15M+71.1% | $20.55M-33.2% | ||
| -19.3%-31.3pp | 12%+2.5pp | 9.5%-8.6pp | 18.1%+5.0pp | 13.1%-3.8pp | ||
| -$0.30-250% | $0.20+25.0% | $0.16-44.8% | $0.29+70.6% | $0.17-32.0% | ||
| -$0.30-225% | $0.24+26.3% | $0.19-42.4% | $0.33+73.7% | $0.19-34.5% | ||
| 104.4M-13.0% | 120M+0.5% | 119.4M-0.9% | 120.5M+0.6% | 119.8M+5.6% | ||
| 104.4M+0.6% | 103.9M+0.3% | 103.5M-0.5% | 104.1M0.0% | 104.1M+0.8% | ||
| -$13.11M+13.6% | -$15.18M— | —— | -$17.76M-29.6% | -$13.71M-255% | ||
| -$7.64M-227% | $6M-45.1% | $10.92M— | —— | $12.93M+516% | ||
| -$20.71M— | —— | $5.06M+84.2% | $2.75M-65.0% | $7.84M— | ||
| $3.27M— | $0-100% | $3.94M-14.8% | $4.63M+865% | -$605K— | ||
| -$9.38M— | —— | $17.16M+192% | $5.88M+199% | -$5.94M-155% | ||
| -$4.74M-247% | $3.22M-76.0% | $13.46M— | —— | $13.53M— | ||
| $760K+102% | -$31.22M+32.7% | -$46.41M+54.9% | -$102.93M-159% | -$39.8M-772% | ||
| $4.54M— | —— | $14.65M-79.1% | $70.13M+2,312% | -$3.17M+95.1% | ||
| -$16.77M-144% | $38.45M-29.4% | $54.48M+23.0% | $44.3M+764% | $5.13M-91.5% | ||
| $0— | $0-100% | $42.46M-58.8% | $103.02M+276% | $27.43M— | ||
| $5.76M-84.2% | $36.54M+348% | $8.15M-34.4% | $12.43M-21.5% | $15.83M+127% | ||
| $201K+302% | $50K— | $0-100% | $57K-45.2% | $104K-14.0% | ||
| $3.98M+39.3% | $2.86M+40.7% | $2.03M-78.0% | $9.24M+431% | $1.74M+95.7% | ||
| $2.54M+3.1% | $2.46M+13.4% | $2.17M-33.7% | $3.28M+91.0% | $1.72M+11.9% | ||
| $164.9M-18.4% | $202.13M-2.7% | $207.64M+6.8% | $194.43M+23.7% | $157.21M-13.6% | ||
| $23.04M+11.0% | $20.77M-9.2% | $22.88M+20.3% | $19.02M-12.9% | $21.83M+30.0% | ||
| -$49.6M-1,205% | $4.49M-56.1% | $10.22M-61.7% | $26.68M+681% | $3.42M-86.5% | ||
| -$49M-1,126% | $4.78M-54.5% | $10.51M-60.8% | $26.78M+591% | $3.88M-84.8% | ||
| -$49M-1,126% | $4.78M-54.5% | $10.51M-60.8% | $26.78M+591% | $3.88M-84.8% | ||
| -29.7%-32.1pp | 2.4%-2.7pp | 5.1%-8.7pp | 13.8%+11.3pp | 2.5%-11.6pp | ||
| -$49.6M-1,205% | $4.49M-56.1% | $10.22M-61.7% | $26.68M+681% | $3.42M-86.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Corcept Therapeutics's revenue?
- Corcept Therapeutics (CORT) generated $769.1M in revenue over the trailing twelve months, up 12.2% year over year.
- Is Corcept Therapeutics profitable?
- Corcept Therapeutics reported $47.3M in net income over the trailing twelve months, a 6.2% net margin.
- What are Corcept Therapeutics's profit margins?
- Gross margin is 98.3% and operating margin is -1.1%, with a 6.2% net margin.
- What is Corcept Therapeutics's earnings per share?
- Corcept Therapeutics's diluted EPS over the trailing twelve months is $0.35.
- Where does Corcept Therapeutics's income statement data come from?
- Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
